BRAVELLE 75UI powder+solvent for injection medication leaflet

G03GA04 urofollitropin • Genito urinary system and sex hormones | Gonadotropins and other ovulation stimulants

Urofolitropin is a medication used in the treatment of infertility in both women and men. It contains purified follicle-stimulating hormone (FSH) obtained from the urine of postmenopausal women. FSH is an essential hormone for ovarian follicle development in women and spermatogenesis in men.

In women, urofolitropin is used to stimulate the ovaries during assisted reproductive procedures such as in vitro fertilization (IVF). In men, it is used to stimulate sperm production in cases of hypogonadotropic hypogonadism.

The medication is administered subcutaneously or intramuscularly, as directed by a physician. The dosage and duration of treatment vary depending on the individual patient's response.

Common side effects include injection site reactions, headache, bloating, and abdominal discomfort. In rare cases, ovarian hyperstimulation syndrome (OHSS) may occur in women.

Urofolitropin is an effective treatment for infertility, helping to increase the chances of conception during assisted reproductive procedures.

General data about BRAVELLE 75UI

Substance: urofollitropin

Date of last drug list: 01-07-2020

Commercial code: W53059002

Concentration: 75UI

Pharmaceutical form: powder+solvent for injection

Quantity: 10

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: FERRING GMBH - GERMANIA

Holder: FERRING GMBH - GERMANIA

Number: 1824/2009/02

Shelf life: 2 years